by Paul | 9th February 2024 | News
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical need The initial trial of OK-101 to treat NCP is designed as a randomized,... by admin | 28th February 2023 | News
OKYO Pharma Limited(“OKYO”, “OKYO Pharma” or the “Company”) OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease London and New York, NY, February 28, 2023 – OKYO Pharma Limited (LSE:...